Modeling resistance and recurrence patterns of combined targeted–chemoradiotherapy predicts benefit of shorter induction period
DM McClatchy, H Willers, AN Hata, Z Piotrowska…�- Cancer research, 2020 - AACR
Optimal integration of molecularly targeted therapies, such as tyrosine kinase inhibitors
(TKI), with concurrent chemotherapy and radiation (CRT) to improve outcomes in genotype�…
(TKI), with concurrent chemotherapy and radiation (CRT) to improve outcomes in genotype�…
MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping
JM Tsai, AN Hata, JK Lennerz�- The Oncologist, 2021 - academic.oup.com
Comprehensive genetic profiling using next-generation sequencing technologies has
become an integral part of precision oncology. Variant annotation requires translating the�…
become an integral part of precision oncology. Variant annotation requires translating the�…
Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer–Transformed EGFR Mutant Non–Small-Cell Lung Cancer
MJ Mooradian, Z Piotrowska, BJ Drapkin…�- JCO precision�…, 2017 - ascopubs.org
Epidermalgrowthfactorreceptor (EGFR) mutation–positive lung cancers respond
dramatically to EGFR tyrosine kinase inhibitors (TKIs), 1-3 and repeat biopsies at acquired�…
dramatically to EGFR tyrosine kinase inhibitors (TKIs), 1-3 and repeat biopsies at acquired�…
Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.
Z Piotrowska, SV Liu, A Muzikansky, N Marcoux… - 2018 - ascopubs.org
e21231 Background: Osimertinib (osi) is a potent, CNS-penetrant 3rd-generation EGFR TKI.
Though older TKIs did not add benefit to chemo (IMPRESS, Soria et al 2015), combining osi�…
Though older TKIs did not add benefit to chemo (IMPRESS, Soria et al 2015), combining osi�…
Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy
AF Farago, BJ Drapkin, A Charles, B Yeap, RS Heist…�- Cancer Research, 2017 - AACR
Background: SCLC is an aggressive high-grade neuroendocrine malignancy. While SCLC
is often highly sensitive to first line platinum based chemotherapy, response rates to second�…
is often highly sensitive to first line platinum based chemotherapy, response rates to second�…
Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile
R Pagliarini, BC Milgram, DR Borrelli…�- European Journal of�…, 2022 - ejcancer.com
Background: EGFR mutations are well validated clinical targets in NSCLC. Osimertinib, a
highly selective EGFR mutation-targeted drug, achieves an objective response rate (ORR)�…
highly selective EGFR mutation-targeted drug, achieves an objective response rate (ORR)�…
Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).
AF Farago, BJ Drapkin, A Charles, BY Yeap, RS Heist… - 2018 - ascopubs.org
8571 Background: SCLC is a high-grade neuroendocrine malignancy with overall response
rates (ORR) to second-line chemotherapy generally ranging from 10-30%. The poly (ADP�…
rates (ORR) to second-line chemotherapy generally ranging from 10-30%. The poly (ADP�…
Combined targeting of MEK and MCL-1 induces apoptosis and tumor regression of KRAS mutant NSCLC
AN Hata, FM Siddiqui, M Gomez-Caraballo, SJ Bilton…�- Cancer Research, 2017 - AACR
There are currently no effective targeted therapeutic strategies for KRAS mutant non-small
cell lung cancer (NSCLC). Single agent MEK inhibitors have demonstrated showed�…
cell lung cancer (NSCLC). Single agent MEK inhibitors have demonstrated showed�…
Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor
Unlike the majority of G protein–coupled receptors, the prostaglandin E2 (PGE2) E-
prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence�…
prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence�…
Investigating new mechanisms of acquired resistance to targeted therapies: if you hit them harder, do they get up differently?
Targeted therapies have revolutionized treatment of several different types of cancers.
However, in almost an invariable fashion, cancers eventually regrow in the presence of the�…
However, in almost an invariable fashion, cancers eventually regrow in the presence of the�…